Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Antihero
|
| gptkbp:approves |
gptkb:2009
gptkb:FDA |
| gptkbp:atccode |
N03 AG01
|
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Sabril
|
| gptkbp:casnumber |
68611-51-2
|
| gptkbp:category |
gptkb:C
|
| gptkbp:chemical_formula |
C8 H15 N3 O3 S
|
| gptkbp:class |
gamma-aminobutyric acid analogue
|
| gptkbp:clinical_trial |
studied in various clinical trials
|
| gptkbp:clinical_use |
used in combination with other medications
|
| gptkbp:contraindication |
hypersensitivity to vigabatrin
|
| gptkbp:country_of_origin |
gptkb:Switzerland
|
| gptkbp:developed_by |
gptkb:Hoffmann-La_Roche
|
| gptkbp:dosage_form |
varies based on condition
|
| gptkbp:duration |
long-term treatment may be necessary
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
oral tablet
powder for oral solution |
| https://www.w3.org/2000/01/rdf-schema#label |
Vigabatrin
|
| gptkbp:indication |
refractory epilepsy
treatment of infantile spasms |
| gptkbp:interacts_with |
may interact with other anticonvulsants
|
| gptkbp:is_effective_against |
effective in reducing seizure frequency
|
| gptkbp:is_monitored_by |
regular vision tests recommended
|
| gptkbp:lifespan |
5 to 8 hours
|
| gptkbp:mechanism_of_action |
GABA transaminase inhibitor
|
| gptkbp:metabolism |
not extensively metabolized
|
| gptkbp:patient_education |
patients should be informed about vision risks
|
| gptkbp:patient_population |
used in adults and children
|
| gptkbp:pharmacokinetics |
bioavailability is high
increases GABA levels in the brain |
| gptkbp:premiered_on |
1 to 2 weeks
|
| gptkbp:replaces |
should be tapered off to avoid seizures
|
| gptkbp:research |
ongoing research for new indications
|
| gptkbp:research_focus |
investigated for potential use in other neurological disorders
|
| gptkbp:safety |
not recommended for use in children under 2 years
|
| gptkbp:safety_measures |
requires regular follow-up with healthcare provider
|
| gptkbp:side_effect |
gptkb:anemia
gptkb:depression fatigue confusion drowsiness weight gain peripheral neuropathy psychosis agitation vision loss |
| gptkbp:storage |
store at room temperature
|
| gptkbp:used_for |
gptkb:epilepsy
infantile spasms complex partial seizures |
| gptkbp:bfsParent |
gptkb:Gabapentin
|
| gptkbp:bfsLayer |
6
|